The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Bioengineered Protein Drugs Market Research Report 2024

Global Bioengineered Protein Drugs Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1413789

No of Pages : 92

Synopsis
The global Bioengineered Protein Drugs market was valued at US$ 83770 million in 2023 and is anticipated to reach US$ 110780 million by 2030, witnessing a CAGR of 4.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Bioengineered Protein Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bioengineered Protein Drugs.
Report Scope
The Bioengineered Protein Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bioengineered Protein Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bioengineered Protein Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dr.Reddy’s
Eli Lilly
Merck
Reliance Life Sciences
Panacea Biotech
Novartis
Fresenius
Sanofi
ProBioGen
GlaxoSmithKline
Roche
Amoytop Biotech
Shanghai United Cell Biotechnology
Hualan Bio
Segment by Type
Monoclonal Antibodies
Therapeutic Proteins
Vaccines
Segment by Application
Cancer
Diabetes
Autoimmune Disorder
Infectious Disease
Neurodegenerative
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bioengineered Protein Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bioengineered Protein Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Bioengineered Protein Drugs Market Overview
1.1 Product Overview and Scope of Bioengineered Protein Drugs
1.2 Bioengineered Protein Drugs Segment by Type
1.2.1 Global Bioengineered Protein Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Monoclonal Antibodies
1.2.3 Therapeutic Proteins
1.2.4 Vaccines
1.3 Bioengineered Protein Drugs Segment by Application
1.3.1 Global Bioengineered Protein Drugs Market Value by Application: (2024-2030)
1.3.2 Cancer
1.3.3 Diabetes
1.3.4 Autoimmune Disorder
1.3.5 Infectious Disease
1.3.6 Neurodegenerative
1.3.7 Others
1.4 Global Bioengineered Protein Drugs Market Size Estimates and Forecasts
1.4.1 Global Bioengineered Protein Drugs Revenue 2019-2030
1.4.2 Global Bioengineered Protein Drugs Sales 2019-2030
1.4.3 Global Bioengineered Protein Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bioengineered Protein Drugs Market Competition by Manufacturers
2.1 Global Bioengineered Protein Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bioengineered Protein Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bioengineered Protein Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Bioengineered Protein Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bioengineered Protein Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bioengineered Protein Drugs, Product Type & Application
2.7 Bioengineered Protein Drugs Market Competitive Situation and Trends
2.7.1 Bioengineered Protein Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bioengineered Protein Drugs Players Market Share by Revenue
2.7.3 Global Bioengineered Protein Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bioengineered Protein Drugs Retrospective Market Scenario by Region
3.1 Global Bioengineered Protein Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bioengineered Protein Drugs Global Bioengineered Protein Drugs Sales by Region: 2019-2030
3.2.1 Global Bioengineered Protein Drugs Sales by Region: 2019-2024
3.2.2 Global Bioengineered Protein Drugs Sales by Region: 2025-2030
3.3 Global Bioengineered Protein Drugs Global Bioengineered Protein Drugs Revenue by Region: 2019-2030
3.3.1 Global Bioengineered Protein Drugs Revenue by Region: 2019-2024
3.3.2 Global Bioengineered Protein Drugs Revenue by Region: 2025-2030
3.4 North America Bioengineered Protein Drugs Market Facts & Figures by Country
3.4.1 North America Bioengineered Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bioengineered Protein Drugs Sales by Country (2019-2030)
3.4.3 North America Bioengineered Protein Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Bioengineered Protein Drugs Market Facts & Figures by Country
3.5.1 Europe Bioengineered Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bioengineered Protein Drugs Sales by Country (2019-2030)
3.5.3 Europe Bioengineered Protein Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bioengineered Protein Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Bioengineered Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bioengineered Protein Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Bioengineered Protein Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Bioengineered Protein Drugs Market Facts & Figures by Country
3.7.1 Latin America Bioengineered Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bioengineered Protein Drugs Sales by Country (2019-2030)
3.7.3 Latin America Bioengineered Protein Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bioengineered Protein Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Bioengineered Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bioengineered Protein Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bioengineered Protein Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Bioengineered Protein Drugs Sales by Type (2019-2030)
4.1.1 Global Bioengineered Protein Drugs Sales by Type (2019-2024)
4.1.2 Global Bioengineered Protein Drugs Sales by Type (2025-2030)
4.1.3 Global Bioengineered Protein Drugs Sales Market Share by Type (2019-2030)
4.2 Global Bioengineered Protein Drugs Revenue by Type (2019-2030)
4.2.1 Global Bioengineered Protein Drugs Revenue by Type (2019-2024)
4.2.2 Global Bioengineered Protein Drugs Revenue by Type (2025-2030)
4.2.3 Global Bioengineered Protein Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Bioengineered Protein Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bioengineered Protein Drugs Sales by Application (2019-2030)
5.1.1 Global Bioengineered Protein Drugs Sales by Application (2019-2024)
5.1.2 Global Bioengineered Protein Drugs Sales by Application (2025-2030)
5.1.3 Global Bioengineered Protein Drugs Sales Market Share by Application (2019-2030)
5.2 Global Bioengineered Protein Drugs Revenue by Application (2019-2030)
5.2.1 Global Bioengineered Protein Drugs Revenue by Application (2019-2024)
5.2.2 Global Bioengineered Protein Drugs Revenue by Application (2025-2030)
5.2.3 Global Bioengineered Protein Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Bioengineered Protein Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Dr.Reddy’s
6.1.1 Dr.Reddy’s Corporation Information
6.1.2 Dr.Reddy’s Description and Business Overview
6.1.3 Dr.Reddy’s Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Dr.Reddy’s Bioengineered Protein Drugs Product Portfolio
6.1.5 Dr.Reddy’s Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Corporation Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly Bioengineered Protein Drugs Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Bioengineered Protein Drugs Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Reliance Life Sciences
6.4.1 Reliance Life Sciences Corporation Information
6.4.2 Reliance Life Sciences Description and Business Overview
6.4.3 Reliance Life Sciences Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Reliance Life Sciences Bioengineered Protein Drugs Product Portfolio
6.4.5 Reliance Life Sciences Recent Developments/Updates
6.5 Panacea Biotech
6.5.1 Panacea Biotech Corporation Information
6.5.2 Panacea Biotech Description and Business Overview
6.5.3 Panacea Biotech Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Panacea Biotech Bioengineered Protein Drugs Product Portfolio
6.5.5 Panacea Biotech Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Novartis Bioengineered Protein Drugs Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Fresenius
6.6.1 Fresenius Corporation Information
6.6.2 Fresenius Description and Business Overview
6.6.3 Fresenius Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Fresenius Bioengineered Protein Drugs Product Portfolio
6.7.5 Fresenius Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sanofi Bioengineered Protein Drugs Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 ProBioGen
6.9.1 ProBioGen Corporation Information
6.9.2 ProBioGen Description and Business Overview
6.9.3 ProBioGen Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 ProBioGen Bioengineered Protein Drugs Product Portfolio
6.9.5 ProBioGen Recent Developments/Updates
6.10 GlaxoSmithKline
6.10.1 GlaxoSmithKline Corporation Information
6.10.2 GlaxoSmithKline Description and Business Overview
6.10.3 GlaxoSmithKline Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 GlaxoSmithKline Bioengineered Protein Drugs Product Portfolio
6.10.5 GlaxoSmithKline Recent Developments/Updates
6.11 Roche
6.11.1 Roche Corporation Information
6.11.2 Roche Bioengineered Protein Drugs Description and Business Overview
6.11.3 Roche Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Roche Bioengineered Protein Drugs Product Portfolio
6.11.5 Roche Recent Developments/Updates
6.12 Amoytop Biotech
6.12.1 Amoytop Biotech Corporation Information
6.12.2 Amoytop Biotech Bioengineered Protein Drugs Description and Business Overview
6.12.3 Amoytop Biotech Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Amoytop Biotech Bioengineered Protein Drugs Product Portfolio
6.12.5 Amoytop Biotech Recent Developments/Updates
6.13 Shanghai United Cell Biotechnology
6.13.1 Shanghai United Cell Biotechnology Corporation Information
6.13.2 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Description and Business Overview
6.13.3 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Product Portfolio
6.13.5 Shanghai United Cell Biotechnology Recent Developments/Updates
6.14 Hualan Bio
6.14.1 Hualan Bio Corporation Information
6.14.2 Hualan Bio Bioengineered Protein Drugs Description and Business Overview
6.14.3 Hualan Bio Bioengineered Protein Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Hualan Bio Bioengineered Protein Drugs Product Portfolio
6.14.5 Hualan Bio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bioengineered Protein Drugs Industry Chain Analysis
7.2 Bioengineered Protein Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bioengineered Protein Drugs Production Mode & Process
7.4 Bioengineered Protein Drugs Sales and Marketing
7.4.1 Bioengineered Protein Drugs Sales Channels
7.4.2 Bioengineered Protein Drugs Distributors
7.5 Bioengineered Protein Drugs Customers
8 Bioengineered Protein Drugs Market Dynamics
8.1 Bioengineered Protein Drugs Industry Trends
8.2 Bioengineered Protein Drugs Market Drivers
8.3 Bioengineered Protein Drugs Market Challenges
8.4 Bioengineered Protein Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’